Antioxidant treatment protects against matrix metalloproteinase activation and cardiomyocyte injury during acute pulmonary thromboembolism

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 385, Issue 7, 2012, Pages 685-696

  Sousa Santos, Ozelia ^a   Neto Neves, Evandro M ^a   Ferraz, Karina C ^b   Ceron, Carla S ^a   Rizzi, Elen ^a   Gerlach, Raquel F ^a   Tanus Santos, Jose E ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Antioxidant; Cardiac troponin I; Cardiomyocyte injury; Matrix metalloproteinases; Reactive oxygen species

Indexed keywords

ANTIOXIDANT; GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE; REACTIVE OXYGEN METABOLITE; SODIUM CHLORIDE; TEMPOL; TROPONIN I;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; FLUOROMETRY; HEART MUSCLE INJURY; HEMODYNAMICS; HUMAN; HUMAN CELL; LUNG ARTERY PRESSURE; LUNG EMBOLISM; LUNG VASCULAR RESISTANCE; MALE; NONHUMAN; OXIDATIVE STRESS; SHEEP;

ANIMALS; ANTIOXIDANTS; BLOOD PRESSURE; CHEMOTAXIS; CYCLIC N-OXIDES; HEART RATE; HEART VENTRICLES; HUMANS; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MYOCYTES, CARDIAC; NEUTROPHILS; PULMONARY EMBOLISM; REACTIVE OXYGEN SPECIES; SHEEP; SPIN LABELS; TROPONIN I;

EID: 84862906071     PISSN: 00281298     EISSN: 14321912     Source Type: Journal    
DOI: 10.1007/s00210-012-0748-9     Document Type: Article

References (42)

1. Ali MA, Cho WJ, Hudson B, Kassiri Z, Granzier H, Schulz R (2010) Titin is a target of matrix metalloproteinase-2: implications in myocardial ischemia/reperfusion injury. Circulation 122(20):2039-2047
2. Castro MM, Rizzi E, Figueiredo-Lopes L, Fernandes K, Bendhack LM, Pitol DL, Gerlach RF, Tanus-Santos JE (2008) Metalloproteinase inhibition ameliorates hypertension and prevents vascular dysfunction and remodeling in renovascular hypertensive rats. Atherosclerosis 198(2):320-331 (Pubitemid 351707391)
3. Castro MM, Rizzi E, Rodrigues GJ, Ceron CS, Bendhack LM, Gerlach RF, Tanus-Santos JE (2009) Antioxidant treatment reduces matrix metalloproteinase-2- induced vascular changes in renovascular hypertension. Free Radic Biol Med 46(9):1298-1307
4. Castro MM, Rizzi E, Prado CM, Rossi MA, Tanus-Santos JE, Gerlach RF (2010) Imbalance between matrix metalloproteinases and tissue inhibitor of metalloproteinases in hypertensive vascular remodeling. Matrix Biol 29(3):194-201
5. Ceron CS, Castro MM, Rizzi E, Montenegro MF, Fontana V, Salgado MC, Gerlach RF, Tanus-Santos JE (2010) Spironolactone and hydrochlorothiazide exert antioxidant effects and reduce vascular matrix metalloproteinase-2 activity and expression in a model of renovascular hypertension. Br J Pharmacol 160(1):77-87
6. Cheung PY, Sawicki G, Wozniak M, Wang W, Radomski MW, Schulz R (2000) Matrix metalloproteinase-2 contributes to ischemia-reperfusion injury in the heart. Circulation 101(15):1833-1839 (Pubitemid 30213106)
7. Chow AK, Cena J, Schulz R (2007) Acute actions and novel targets of matrix metalloproteinases in the heart and vasculature. Br J Pharmacol 152(2):189-205 (Pubitemid 47517601)
8. DeMarco VG, Habibi J, Whaley-Connell AT, Schneider RI, Heller RL, Bosanquet JP, Hayden MR, Delcour K, Cooper SA, Andresen BT, Sowers JR, Dellsperger KC (2008) Oxidative stress contributes to pulmonary hypertension in the transgenic (mRen2)27 rat. Am J Physiol Heart Circ Physiol 294(6):H2659-H2668
9. Dias-Junior CA, Souza-Costa DC, Zerbini T, da Rocha JB, Gerlach RF, Tanus-Santos JE (2005) The effect of sildenafil on pulmonary embolism-induced oxidative stress and pulmonary hypertension. Anesth Analg 101(1):115-120 (Pubitemid 40853360)
10. Dias-Junior CA, Gladwin MT, Tanus-Santos JE (2006) Low-dose intravenous nitrite improves hemodynamics in a canine model of acute pulmonary thromboembolism. Free Radic Biol Med 41 (12):1764-1770 (Pubitemid 44848399)
11. Dias-Junior CA, Montenegro MF, Florencio BC, Tanus-Santos JE (2008) Sildenafil improves the beneficial haemodynamic effects of intravenous nitrite infusion during acute pulmonary embolism. Basic Clin Pharmacol Toxicol 103(4):374-379
12. Dias-Junior CA, Neto-Neves EM, Montenegro MF, Tanus-Santos JE (2010) Hemodynamic effects of inducible nitric oxide synthase inhibition combined with sildenafil during acute pulmonary embolism. Nitric Oxide 23(4):284-288
13. Elmedal B, de Dam MY, Mulvany MJ, Simonsen U (2004) The superoxide dismutase mimetic, tempol, blunts right ventricular hypertrophy in chronic hypoxic rats. Br J Pharmacol 141(1):105-113 (Pubitemid 38241168)
14. Fortuna GM, Figueiredo-Lopes L, Dias-Junior CA, Gerlach RF, Tanus-Santos JE (2007) A role for matrix metalloproteinase-9 in the hemodynamic changes following acute pulmonary embolism. Int J Cardiol 114(1):22-27 (Pubitemid 44791467)
15. Horlander KT, Leeper KV (2003) Troponin levels as a guide to treatment of pulmonary embolism. Curr Opin Pulm Med 9(5):374-377 (Pubitemid 36994064)
16. Kandasamy AD, Chow AK, Ali MA, Schulz R (2010) Matrix metalloproteinase-2 and myocardial oxidative stress injury: beyond the matrix. Cardiovasc Res 85(3):413-423
17. Kappert K, Sparwel J, Sandin A, Seiler A, Siebolts U, Leppanen O, Rosenkranz S, Ostman A (2006) Antioxidants relieve phosphatase inhibition and reduce PDGF signaling in cultured VSMCS and in restenosis. Arterioscler Thromb Vasc Biol 26(12):2644-2651
18. Konstantinides S, Geibel A, Olschewski M, Kasper W, Hruska N, Jackle S, Binder L (2002) Importance of cardiac troponins I and T in risk stratification of patients with acute pulmonary embolism. Circulation 106(10):1263-1268 (Pubitemid 34988646)
19. Kucher N, Goldhaber SZ (2003) Cardiac biomarkers for risk stratification of patients with acute pulmonary embolism. Circulation 108(18):2191-2194 (Pubitemid 37363033)
20. Lalu MM, Pasini E, Schulze CJ, Ferrari-Vivaldi M, Ferrari-Vivaldi G, Bachetti T, Schulz R (2005) Ischaemia-reperfusion injury activates matrix metalloproteinases in the human heart. Eur Heart J 26(1):27-35 (Pubitemid 40221120)
21. Liaw WJ, Chen TH, Lai ZZ, Chen SJ, Chen A, Tzao C, Wu JY, Wu CC (2005) Effects of a membrane-permeable radical scavenger, tempol, on intraperitoneal sepsis-induced organ injury in rats. Shock 23(1):88-96 (Pubitemid 40083033)
22. Lualdi JC, Goldhaber SZ (1995) Right ventricular dysfunction after acute pulmonary embolism: pathophysiologic factors, detection, and therapeutic implications. Am Heart J 130(6):1276-1282
23. Montenegro MF, Neto-Neves EM, Dias-Junior CA, Ceron CS, Castro MM, Gomes VA, Kanashiro A, Tanus-Santos JE (2010) Quercetin restores plasma nitrite and nitroso species levels in renovascular hypertension. Naunyn Schmiedebergs Arch Pharmacol 382 (4):293-301
24. Neto-Neves EM, Dias-Junior CA, Rizzi E, Castro MM, Sonego F, Gerlach RF, Tanus-Santos JE (2011) Metalloproteinase inhibition protects against cardiomyocyte injury during experimental acute pulmonary thromboembolism. Crit Care Med 39(2):349-356
25. Okamoto T, Akaike T, Sawa T, Miyamoto Y, van der Vliet A, Maeda H (2001) Activation of matrix metalloproteinases by peroxynitriteinduced protein S-glutathiolation via disulfide S-oxide formation. J Biol Chem 276(31):29596-29602
26. Palei AC, Zaneti RA, Fortuna GM, Gerlach RF, Tanus-Santos JE (2005) Hemodynamic benefits of matrix metalloproteinase-9 inhibition by doxycycline during experimental acute pulmonary embolism. Angiology 56(5):611-617 (Pubitemid 41383315)
27. Parikh SV, de Lemos JA (2006) Biomarkers in cardiovascular disease: integrating pathophysiology into clinical practice. Am J Med Sci 332(4):186-197 (Pubitemid 44563805)
28. Sawicki G, Leon H, Sawicka J, Sariahmetoglu M, Schulze CJ, Scott PG, Szczesna-Cordary D, Schulz R (2005) Degradation of myosin light chain in isolated rat hearts subjected to ischemia-reperfusion injury: a new intracellular target for matrix metalloproteinase-2. Circulation 112(4):544-552 (Pubitemid 41060795)
29. Schulz R (2007) Intracellular targets of matrix metalloproteinase-2 in cardiac disease: rationale and therapeutic approaches. Annu Rev Pharmacol Toxicol 47:211-242
30. Simonsen U, Christensen FH, Buus NH (2009) The effect of tempol on endothelium-dependent vasodilatation and blood pressure. Pharmacol Ther 122(2):109-124
31. Smulders YM (2001) Contribution of pulmonary vasoconstriction to haemodynamic instability after acute pulmonary embolism. Implications for treatment? Neth J Med 58(6):241-247 (Pubitemid 32611649)
32. 4, and fMLP: inhibition of actin polymerization. J Nat Prod 74(2):113-118
33. Souza-Costa DC, Zerbini T, Palei AC, Gerlach RF, Tanus-Santos JE (2005) L-Arginine attenuates acute pulmonary embolism-induced increases in lung matrix metalloproteinase-2 and matrix metalloproteinase-9. Chest 128(5):3705-3710 (Pubitemid 41698717)
34. Souza-Costa DC, Figueiredo-Lopes L, Alves-Filho JC, Semprini MC, Gerlach RF, Cunha FQ, Tanus-Santos JE (2007) Protective effects of atorvastatin in rat models of acute pulmonary embolism: involvement of matrix metalloproteinase-9. Crit Care Med 35 (1):239-245 (Pubitemid 46035701)
35. Teke Z, Kabay B, Ozden A, Yenisey C, Bir F, Demirkan NC, Bicakci T, Erdem E (2008) Effects of tempol, a membrane-permeable radical scavenger, on local and remote organ injuries caused by intestinal ischemia/reperfusion in rats. J Surg Res 149(2):259-271
36. Uzuelli JA, Dias-Junior CA, Tanus-Santos JE (2008) Severity dependent increases in circulating cardiac troponin I and MMP-9 concentrations after experimental acute pulmonary thromboembolism. Clin Chim Acta 388(1-2):184-188 (Pubitemid 350266594)
37. Van den Steen PE, Dubois B, Nelissen I, Rudd PM, Dwek RA, Opdenakker G (2002) Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9). Crit Rev Biochem Mol Biol 37(6):375-536 (Pubitemid 36071972)
38. Van Wart HE, Birkedal-Hansen H (1990) The cysteine switch: a principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family. Proc Natl Acad Sci USA 87:5578-5582
39. Wang W, Schulze CJ, Suarez-Pinzon WL, Dyck JR, Sawicki G, Schulz R (2002) Intracellular action of matrix metalloproteinase-2 accounts for acute myocardial ischemia and reperfusion injury. Circulation 106(12):1543-1549
40. Watts JA, Zagorski J, Gellar MA, Stevinson BG, Kline JA (2006) Cardiac inflammation contributes to right ventricular dysfunction following experimental pulmonary embolism in rats. J Mol Cell Cardiol 41(2):296-307 (Pubitemid 44080220)
41. Watts JA, Gellar MA, Obraztsova M, Kline JA, Zagorski J (2008) Role of inflammation in right ventricular damage and repair following experimental pulmonary embolism in rats. Int J Exp Pathol 89(5):389-399
42. Wood KE (2002) Major pulmonary embolism: review of a pathophysiologic approach to the golden hour of hemodynamically significant pulmonary embolism. Chest 121(3):877-905 (Pubitemid 34251458)